secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clene Inc. (CLNN)
CIK:        0001822791
Form:       8-K
Filed at:   2023-06-16T23:59:59+00:00
Accession:  0001437749-23-017739
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clene raises $40M in public offering of common stock and warrants; net ~$37.4M for CNM-Au8
--------------------------------------------------------------------------------

- Offers 50M shares + 50M Tranche A warrants ($1.10 strike) + 50M Tranche B warrants ($1.50 strike) at $0.80/unit.
- Gross proceeds ~$40M; estimated net ~$37.4M after discounts and expenses.
- Warrant expiration tied to FDA NDA acceptance (Tranche A) or approval (Tranche B), with final dates 2026/2030.
- Proceeds to fund CNM-Au8 clinical trials, regulatory filings, commercialization, and general corporate purposes.
- Closing expected June 21, 2023; Canaccord Genuity sole bookrunner, Maxim Group and EF Hutton co-managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923017739/0001437749-23-017739-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822791/000143774923017739/clnn20230612_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-017739

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer